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Abstract A chemiluminescence enzyme immunoassay based on magnetic microparticles (MmPs-
CLEIA) was developed to evaluate serum a-fetoprotein (AFP) in parallel with traditional colorimetric
enzyme-linked immunosorbent assay (ELISA). A systematic comparison between the MmPs-CLEIA
and colorimetric ELISA concluded that the MPs-CLEIA exhibited fewer dosages of immunoreagents,
less total assay time, and better linearity, recovery, precision, sensitivity and validity. AFP was detected
in forty human serum samples by the proposed MPs-CLEIA and ELISA, and the results were
compared with commercial electrochemiluminescence immunoassay (ECLIA) kit. The correlation
coefﬁcient between MPs-CLEIA and ELISA was obtained with R2¼0.6703; however, the correlation
between MPs-CLEIA and ECLIA (R2¼0.9582) was obviously better than that between colorimetric
ELISA and ECLIA (R2¼0.6866).
& 2011 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.
1. Introduction
Enzyme immunoassay (EIA) is a kind of immunoassay that uses
enzyme labeled antibody/antigen to detect antigen/antibody, and
is well known in the bio-analytical ﬁeld [1,2]. The most common
detection method of EIA is enzyme-linked immunosorbent assay
(ELISA). ELISA was ﬁrst reported by Engvall and Perlmann in
1971 [3] and has been widely used as a diagnostic tool in clinic
[4,5], plant pathology [6] and food industry [7]. However, the
need to detect increasingly smaller amounts of target molecules
has led to the emergence of more sensitive indicators, such as
ﬂuorescence and chemiluminescence.
Since reported by Woodhead in 1985 [8], chemiluminescence
immunoassay (CLIA) has been applied broadly to the clinical
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Comparison of CLEIA with ELISA for detection of AFP 131diagnosis and environmental analysis. In initial stages, CLIA
generally used chemiluminescent indicator [9,10], such as lumi-
nol, isoluminol, acridinium ester and so on, directly labeling
antigen (antibody). Although CLIA has improved the analytical
sensitivity of immunoassays, direct labeling of chemiluminescent
indicator was limited by a relatively short duration of light
output, so its application needed robot to assist. Consequently,
chemiluminescence enzyme immunoassay (CLEIA) is developed
based on enzyme–antibody conjugates using a chemiluminescent
substrate, and luminometer was used for measurements. In this
way, CLEIA with improved duration of light output is developed
quickly in recent years. Further to improve the performance,
magnetic microparticles have been applied in CLEIA as separat-
ing agent [11–14] and solid phase [15–17] with higher sensitivity
and larger detection linear range. Although many reports
declared that CLEIA had obvious advantages over ELISA, no
detail work has been done so far to compare them in terms of the
performance and mechanism.
We have focused on determining the a-fetoprotein (AFP)
in human serum. AFP, as a well-established tumor marker
relating to hepatocellular carcinoma (HCC) [18], is recom-
mended by the European Association for the Study of the
Liver, the British Society of Gastroenterology, the European
Group on Tumor Markers, the National Academy of Clinical
Biochemistry, and the National Comprehensive Cancer
Network. It is necessary for serial AFP measurements together
with consideration of sustained increases in AFP even at low
concentrations [19,20]. Thus sensitive and time-saving meth-
ods for the detection of AFP are an imperative demand in
clinical diagnosis and prognosis of HCC.
In our work, magnetic microparticles based CLEIA
(MPs-CLEIA) was developed to detect AFP in human serum
in parallel with colorimetric ELISA. MPs-CLEIA was com-
pared systematically with colorimetric ELISA in terms of the
dosage of capture antibody, detection antibody, and analytical
parameters. The advance performance of MPs-CLEIA and the
role of magnetic microparticles in MPs-CLEIA were discussed
according to the results in this work.2. Experimental
2.1. Chemicals and immunoreagents
Mouse anti-human AFP monoclonal antibodies (McAbs) and
AFP were purchased from Fitzgerald Industries International,
Inc. (MA, USA). HRP labeled anti-AFP antibody (HRP-AFP
Abs) was offered by Beijing Chemclin. Biotech. Co., Ltd
(Beijing, China). Chemiluminescent substrates (Luminol,
H2O2 and enhancer) were purchased from Monobind Inc.
(California, USA). HRP Substrate TMB Solutions for ELISA
was purchased from Thermo Fisher Scientiﬁc Inc. (Rockford,
USA). The magnetic particles (2-mm, 0.1%, w/v) modiﬁed
with amino groups (MP-Amine) were purchased from Shang-
hai Allrun Nano Science&Tecnology Co., Ltd. (Shanghai,
China). All other relating chemicals were purchased form
Sigma-Aldrich (St. Louis, MO, USA).
Highly distilled and deionized water was used throughout.
The washing solution was 0.1 M PBS buffer (pH 7.4) with
0.5% (w/v) saline solution and 0.05% (v/v) Tween-20. The
AFP stock solution of 100 mg/mL was prepared in 5% bovine
serum and stored at 20 1C. Carbonate buffer was used ascoating buffer. Disinfectant equine serum was used as cali-
brator matrix. The human sera from local hospitals were
collected and analyzed without any pretreatment.
2.2. Apparatus
BHP9504 microtiter plate reader for chemiluminescence inten-
sity detection was purchased from Hamamatsu (Hamamatsu
Co., Ltd., Beijing, China). ELISA analyzer was purchased
from Bio-Rab (USA). C96 MicroWellTM Plates and Immu-
noTM Tubes (polysorpTM) were purchased from Nunc
(Roskilde, Denmark). The incubation and shaking procedures
at 37 1C were carried out at a thermostatic culture oscillator
(ZHWY-100, Shanghai Zhicheng Analytical Instrument
Manufacturing Co., Ltd., Shanghai, China). A microplate
mixer (Beijing Xinjingke Biotechnology Co., Ltd., Beijing,
China) was employed to blend the solutions in microwells.
ADEM-3 microtiter plate washer (Beijing Tuopu Analytical
Instrument Co., Ltd., Beijing, China) was used.
2.3. Immunoassay procedure of ELISA
2.3.1. Preparation of anti-AFP McAbs coated C96
MicroWellTM Plates
An aliquot of 100 mL of AFP McAbs (5 mg/mL) was added
into each well of C96 MicroWellTM Plates, and then stored at
4 1C overnight. During incubation, anti-AFP McAbs were
physically adsorbed to microwells through hydrophobic inter-
action. Afterwards, the microplates were washed with PBS
buffer (with 4% Tween-20) three times to eliminate the free
antibodies. Next, bovine serum albumin (BSA) buffer (5%, w/
v) of 500 mL were added to block the vacant sites for a period
of 12 h at 4 1C. Finally, the prepared microplates were washed
and dried off, then stored at 4 1C for further use.
2.3.2. The procedure of colorimetric ELISA
The immunoassay procedure of colorimetric ELISA is displayed
in Fig. 1(A). An aliquot of 25 mL AFP calibrators or serum
samples, and 50 mL HRP-AFP Abs (dilution ratio of 1:10,000)
were added into the microplates stepwise, and incubated for
90 min at 37 1C. After the sandwich reaction, the microplates
were washed ﬁve times and the remaining solution was removed
by gently tapping the microplates against tissue paper. Finally,
HRP ELISA substrate was added and the absorbance was
measured as optical density (OD).
2.4. Immunoassay procedure of MPs-CLEIA
2.4.1. Preparation of anti-AFP antibody coated MPs
(MPs-anti-AFP Abs)
Before coating anti-AFP McAbs to MPs-Amine, MPs-Amine
were washed two times with 1 mL 2-(N-morpholino)ethanesul-
fonic acid (MES) buffer using the magnetic separator. Next,
MPs-Amine was resuspended in 0.25 mL MES buffer contain-
ing 10 mg (N-Ethyl-N0-(3-dimethylaminopropyl)carbodiimide
hydrochloride) EDC HCl, and then anti-AFP McAbs were
added to the MPs-Amine. Furthermore, the mixture was
incubated on a shaker for 2 h at room temperature. After that
MPs-anti-AFP McAbs were formed. Finally MPs-anti-AFP
McAbs were washed three times and suspended in storage buffer
for further use.
Figure 1 Principles for the evaluation of a-fetoprotein in human serum by HRP-based enzyme immunoassay. (A) Chemiluminescence
immunoassay based on magnetic particles; (B) colorimetric ELISA.
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The procedure of the MPs-CLEIA is presented in Fig. 1(B).
First, an aliquot of 50 mL AFP calibrators or serum samples,
50 mL MPs-anti-AFP McAbs, and 50 mL HRP-AFP Abs
(dilution ratio of 1:20,000) were added into ImmunoTM Tubes
stepwise, and incubated for 30 min with gentle shaking at
37 1C. After the sandwich reaction, total four times washing
was performed by using the samarium–cobalt magnet to
separate the sandwich complex and the unbound reagent.
Finally, 250 mL substrate solution (A and B solutions were
mixed together with 1:1 ratio) was added. The mixture was
incubated for 5 min at room temperature and the emitted
photons as relative light unit (RLU) were measured.Figure 2 Inﬂuence of concentration of anti-AFP McAbs (coating
antibodies) used in the ELISA and MPs-CLEIA. RLU was the
relative light unit; RLUS0 was resulted from determination the
concentration of AFP with calibrator S0, the same with RLUS1
and RLUS5. OD was the optical density, such as ODS0 was
resulted from determination the concentration of AFP with
calibrator S0, the same with ODS1 and ODS5.3. Results and discussion
3.1. Optimization of the concentration of immobilized
anti-AFP antibodies and evaluating the performances
Anti-AFP McAbs were diluted by 20% bovine serum into 1, 1.5,
2, 2.5, 5, 10 and 20 mg/mL. The concentration of anti-AFP
McAbs used in the ELISA and MPs-CLEIA was optimized and
compared. As shown in the Fig. 2, ODS1/ODS0 and ODS5/ODS0
increased with increasing the concentration of coated antibodies
and reached a platform at the concentration of 5 mg/mL, while
RLUS1/RLUS0 and RLUS5/RLUS0 reached a platform merely at
1.5 mg/mL. The results indicated that anti-AFP McAbs physically
adsorbed on microplates would get saturation at the concentration
of 5 mg/mL, and abundant antibodies adsorbed on microwells
would damage the bioactivity of antibodies. However, by cova-
lently conjugated to MPs-Amine surfaces, anti-AFP Abs pre-
sented a high coating efﬁciency and the structure of anti-AFP Abs
would be resulted in a less distortion compared with anti-AFP
Abs physically adsorbed on microwells.
3.2. Optimization and comparison of the concentration of
HRP-AFP Abs
The concentration of HRP-AFP Abs is another important factor
to the sensitivity and working range. Therefore ﬁve dilution
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prepared. The concentration of HRP-AFP Abs used in the
ELISA and MPs-CLEIA was optimized and compared by
evaluating ODS1/ODS0 and ODS5/ODS0, RLUS1/RLUS0 and
RLUS5/RLUS0, respectively (Fig. 3). ODS1/ODS0 increased with
the dilution ratio increasing and reached maximum at the ratio
of 1:10,000, at the same time ODS5/ODS0 increased with the
dilution ratio and reached a short platform at the ratio of 1:8000.
Therefore, dilution ratio of 1:10,000 is appropriate for the
ELISA with a higher sensitivity and better linearity. With similar
situation, we found that dilution ratio of 1:20,000 was appro-
priate for the MPs-CLEIA. The dosage of HRP-AFP Abs
for MPs-CLEIA was half of that for colorimetric ELISA. The
results could be explained by the fact that detecting emitted
luminescence by counting photons coupled with the photomul-
tiplier was much more sensitive than colorimetric ELISA by
accumulating absorbance value.3.3. Optimization and comparison of immunoreaction time
The time for the immunoreagents to interact is one of the key
parameters determining the sensitivity of the immunoassay.
The inﬂuence of the immunoreaction time of ELISA and CLEIA
was studied. In Fig. 4, RLUs of MPs-CLEIA decreased and the
calibration curve got worse after 30 min immunoreaction, so the
immunoreaction time for MPs-CLEIA was ﬁxed at 30 min.Figure 3 Inﬂuence of concentration of HRP-AFP Abs used in the
ELISA and MPs-CLEIA. Calibrators of S0, S1 and S5 were applied
to the optimization.While, ODs of ELISA reached a platform after 90 min and the
calibration curve got a better linearity, so the immunoreaction
time for ELISA was 90 min. The less immunoreaction time for
MPs-CLEIA was mainly due to that the large speciﬁc surface
area of MPs exerted an active role in accelerating the reaction.
On the other hand, the suspension of MPs during reaction
reduced the dilution distance of immunoreagents, and thus
speeded up the rate of reaction.
3.4. Analytical parameters
The calibration, linear range, sensitivity, total assay time of
the two methods were studied and compared systematically.
The results are listed in Table 1. As can be seen, the linear
detection range of MPs-CLEIA increased four times more
than that of ELISA, and the total assay time of MPs-CLEIA
was much less than ELISA. The immunoassay time of MPs-
CLEIA was much shorter than ELISA, which might be due to
immunoreactions between antigens and antibodies being
carried out in a homogeneous mixture and decreasing diffu-
sion distance. While, AFP antibodies coated in microplates in
ELISA were restricted on the coating surface, thus immunor-
eaction time increased because of diffusion effect.Figure 4 Inﬂuence of the immunoreaction time of ELISA and
MPs-CLEIA. Three calibrators of S0, S1 and S5 were applied to
the optimization.
Table 1 Comparison of some of the analytical parameters.
Method Calibration
curve
Linear range
(ng/mL)
Sensitivity
(ng/ml)
Immunoassay
time (min)
Total assay
time (min)
MPs-CLEIA Y¼1.8432þ0.9735X (R2¼0.9980) 10–2500 0.74 30 50
Colorimetric ELISA Y¼1.8707þ1.2160X (R2¼0.9934) 15–600 0.82 90 120
Table 2 Recoveries of AFP from human serum samples
(n¼3).
Method AFP
samples
(ng/mL)
AFP
added
(ng/mL)
AFP
determined
(ng/mL)
Recovery
(%)
Colorimetric
ELISA
1.55 600 554.87 92
1.55 110 97.78 87
1.55 17.5 16.04 86
MPs-CLEIA 1.55 600 587.96 98
1.55 110 117.78 105
1.55 17.5 17.85 93
Figure 5 Linearity-dilution effect of ELISA and MPs-CLEIA.
The serum sample with high AFP level was diluted stepwise with
the calibrator matrix.
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(0.74 ng/mL) was slightly lower than that of ELISA (0.82 ng/
mL), but the regression line of the MPs-CLEIA calibration
cure (R2¼0.9980) was better than that of colorimetric ELISA
(R2¼0.9934), and the slope of the MPs-CLEIA calibration
curve (1.319) was higher than that of ELISA (0.9372), tending
to show that MPs-CLEIA is more precise and sensitive than
ELISA for AFP quantiﬁcation. The linear-dilution effect test
also indicated that MPs-CLEIA was more sensitive and precise
over ELISA. One of the key factors for the proposed
MPs-CLEIA showing better performances over ELISA about
sensitive and precise was that MPs-CLEIA exhibited a larger
linear detection range and a higher slope of the calibration
curve.
3.5. Recovery test
Recovery test is taken by adding quantity of AFP antigen to the
normal human serum. Then the real value is detected. Recovery
rate¼(RH)/A 100%. Samples that included high, middle and
low value in the detectable range were taken to do the recovery
test. The results are shown in Table 2. The recoveries of both
methods were between 90% and 105% (between 85% and 105%
is well acceptable in immunoassay kit development).
3.6. Validity
Linearity-dilution effect is an indicator of validity of the proposed
method. A serum sample with high AFP level was diluted stepwise
by the calibrator matrix (disinfectant equine serum), and the ﬁnal
diluted samples were detected with the proposedMPs-CLEIA and
ELISA. Linearity-dilution curve (Fig. 5) of MPs-CLEIA showed
a good linear, while with ELISA the concentration of AFP
detected did not ﬁt a linear correlation with the dilution ratios.
The results prove that the MPs-CLEIA is reliable in determining
AFP with high concentration in serum samples.3.7. Determination of AFP in serum samples by CLEIA and
ELISA and comparison with commercial ECLIA kit
The proposed MPs-CLEIA and colorimetric ELISA were
applied to evaluate AFP in human serum samples. The results
obtained using the proposed method in the determination of
AFP in fourty clinical sera samples were compared with those
obtained by the commercially available ECLIA kit. As can be
seen in Fig. 6, the correlation coefﬁcient between MPs-CLEIA
and ELISA was 0.6703, and that between ELISA and ECLIA
was 0.6866, while the correlation coefﬁcient between MPs-
CLEIA and ECLIA was 0.9582. There was much better
agreement between MPs-CLEIA and ECLIA than that between
ELISA and ECLIA indicating that not only the bioactivity of
antibodies but indicators could inﬂuence the detection precision.4. Conclusion
In the present work, the construction and systemically compar-
ison of MPs-CLEIA with colorimetric ELISA were performed
for detection of serum AFP. The MPs-CLEIA was proved to be
apparently advantageous over the ELISA in terms of less dosage
of immunoreagents, higher dose hook effect and bioactivity of
immunoreagents, less assay time and wider linear range.
MPs-CLEIA was used to evaluate AFP in human sera samples
and a good correlation was obtained when comparing the results
with that from a commercial electrochemiluminescence immu-
noassay kit. All of these indicated that in the clinical diagnosis,
the MPs-CLEIA for detecting of AFP was a convenient,
economical, and time-saving method for screening, prognosis
and monitoring of HCC.
Figure 6 Evaluation of AFP in human serum samples with
MPs-CLEIA, ELISA and ECLIA.
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